Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Añadir filtros








Intervalo de año
1.
Journal of Zhejiang University. Medical sciences ; (6): 115-118, 2014.
Artículo en Chino | WPRIM | ID: wpr-251713

RESUMEN

The standard first-line treatment of castration-resistant prostate cancer (CRPC) is docetaxel-based chemotherapy. However, CRPC may not respond to docetaxel due to drug resistance or other causes. Several new therapeutic agents have been developed, some of which are approved by FDA or on clinical trials. The mechanisms of action of these agents include stabilizing microtubules, inhibiting hormone synthesis, blocking androgen receptor, bone targeting or immune regulation. In this article we review the novel therapeutic options for CPRC after docetaxel failure.


Asunto(s)
Humanos , Masculino , Neoplasias Óseas , Quimioterapia , Resistencia a Antineoplásicos , Neoplasias de la Próstata Resistentes a la Castración , Quimioterapia , Patología , Taxoides , Usos Terapéuticos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA